Guía para el Trastorno Neurocognoscitivo Mayor

Vigilancia del Progreso de la Implementación para el Diagnóstico y Tratamiento de la Demencia

I Instituto de Evaluación Tecnológica en Salud

6.11

Se hace necesario el fortalecimiento de los sistemas de información y la generación de indicadores propios de la implementación y adherencia de las GPC por parte de los profesionales de la salud y de los pacientes y usuarios. Así mismo la caracterización adecuada del contexto y de las posibles barreras de implementación (10).

Otro estudio plantea la necesidad de hacer seguimiento de la incorporación de una cultura de consumo crítico de la literatura (11), concluyeron que a pesar de que los principios de la medicina basada en la evidencia, dominan el desarrollo metodológico de las guía de práctica clínica y, en sí misma, la práctica clínica, no existe evidencia de la evaluación de dichos procesos, solo de programas que han demostrado de una u otra manera ser efectivos a pesar de no ser afines a la medicina basada en la evidencia.

Dichos programas le apuntan a ser fuertemente efectivos en los procesos de difusión e implementación, dejando de producto final la adopción de dichas recomendaciones. El proceso de vigilancia se basará en dichos ejercicios de manera periódica y necesariamente reinventados, si es necesario a partir del contexto social, político y cultural.

6.12 Análisis del contexto (identificación y análisis de barreras)

La segunda etapa incluye el proceso llevado a cabo por el consenso, la aplicación del instrumento GLIA para el análisis de la posibilidad de implementar las recomendaciones desarrolladas en la guía de práctica clínica, y la construcción de indicadores de seguimiento y evaluación de la implementación de las recomendaciones indicadoras.

Referencias

1. Arango C, Ayuso J, Vieta E, Bagney A, Baeza I, Bobes T, et al. Asociación Americana îe Psiquiatría, Manual diagnóstico y estadístico de los trastornos mentales (DSM-5®), 5a Eî. Arlington, VA, Asociación Americana îe Psiquiatría, 2014 ISB. 978-84-9835-810-0.
2. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Et al.Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 2011: 7(3): 280–292
3. Julie MD and Ganguli MD. Dementia and Cognitive Impairment: Epidemiology, Diagnosis, and Treatment. Clin Geriatr Med 2014: 30 (3): 421–442
4. Gomez C, Hernandez G, Rojas A, Santacruz H, Uribe M. Psiquiatría clínica: diagnóstico y tratamiento en niños, adolescentes y adultos. Medica Panamericana. 2008 ISB: 9789588443010; Pag 410
5. Demencia: una prioridad de salud pública. Washington, DC: OPS, 2013 Disponible en: http://www.who.int/mental_health/publications/dementia_report_2012/es/
6. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001; 20 (357): 169–75
7. Consultado el 24 de febrero de 2017, Demencia Disponible: http://www.who.int/mediacentre/factsheets/fs362/es/
8. Fitzpatrick AL, Kuller LH, Lopez OL, Kawas CH, Jagust W. Survival following dementia onset: Alzheimer’s disease and vascular dementia. J Neurol Sci. 2005, 15;229-230.
9. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013, 2015; 385 (9963), 117-171. DOI: http://dx.doi.org/10.1016/S0140-6736(14)61682-2.
10. GBD 2015 Mortality and Causes of Death Collaborators.Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015, 2016; 388 (10053), 1459-1544. DOI: http://dx.doi.org/10.1016/S0140-6736(16)31012-1.
11. Wimo A, Prince M. World Alzheimer Report 2010 – The Global Economic Impact of Dementia. Alzheimer’s Disease International London, 2010. 96
12. Orden LY, Carrasquilla G, Director G, Médico DP, Cristina A, Alvarez P, et al. Guía Metodológica para la elaboración de Guías de Práctica Clínica con Evaluación Económica en el Sistema General de Seguridad Social en Salud Colombiano Marzo de 2014 Revisores pares nacionales revisores pares internacionales. Colombia; 2014. 154 p
13. NHMRC. Clinical practice guidelines and principles of care for people with dementia. Australia; 2016. ISBN Online: 978-0-9945415-2-9.
14. Organización Mundial de la Salud (OMS). Guía De Intervención Mhgap [Internet]. Guía de Intervención mhGAP, 2011. 1-5
15. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: Advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol. 2010;63(12):1308–11.
16. Toolkit a R. Guideline Adaptation : Update. 2009.
17. Nice SCI for E. L -NICE-SCIE Guideline On Supporting People With Dementia and Their Carers In Health and Social Care. Practice. British; 2006. 66-68
18. NHMRC. Procedures and requirements for meeting the 2011 NHMRC standard for clinical practice guidelines: Version 1.1. Australia; 2011. 32
19. Grasel E, Wiltfang J, Kornhuber J. Non-drug therapies for dementia: an overview of the current situation with regard to proof of effectiveness. Dement Geriatr Cogn Disord. 2003;15:115–125.
20. Australian Government: National Health and Medical Research Council. An ethical framework for integrating palliative care principles into the management of advanced chronic or terminal conditions. 2011. Disponible en: http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/rec31_ethical_framework_palliative_care_terminal_110908.pdf
21. Steinberg M, Corcoran C, Tschanz JT, et al. Risk factors for neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2006;21:824–83
22. Travers C, Gray L, Hubbard R. Evidence for the safety and quality issues associated with the care of patients with cognitive impairment in acute care settings: a rapid review October 2013; 140.
23. Sansoni JD, C.; Grootemaat, P.; Samsa, P.; Capell, J.; Westera A. Younger onset dementia: a literature review: Centre for Health Service Development. Univ Wollongong. 2014;
24. Duane F, Brasher K, Koch S. Living alone with dementia. Dementia. 2013;12(1):123–36.
25. Forbes DA, Morgan D, Janzen BL. Rural and Urban Canadians with Dementia: Use of Health Care Services. Can J Aging / La Rev Can du Vieil. 2010 Mar 31 [cited 2017 Jan 15];25(3):321.
26.
27. Koch T ISE-EP. Rapid appraisal of barriers to the diagnosis and management of patients with dementia in primary care: a systematic review. BMC Fam Pract. 2010;11(52).
28. Cattel C, Gambassi G SA. Correlates of delayed referral for the diagnosis of dementia in an outpatient population. journals Gerontol. 2000;55(2):98–102.
29. Bridges-Webb C, Giles B SC. Patients with dementia and their carers in general practice. Aust Fam Physician. 2006;35(11):923–4.
30. Radford K, Mack HA, Draper B, Chalkley S, Daylight G, Cumming R, et al. Prevalence of dementia in urban and regional Aboriginal Australians. Alzheimer’s Dement. 2015;11(3):271–9.
31. Smith K, Flicker L LN. High prevalence of dementia and cognitive impairment in Indigenous Australians. Neurology. 2008;71(19):1470–3.
32. Bunn F, Goodman C SK. Psychosocial Factors That Shape Patient and Carer Experiences of Dementia Diagnosis and Treatment: A Systematic Review of Qualitative Studies. PLoS One. 2012;9(10):1001331.
33. Health AGD of. Health assessment for people aged 75 years and older. 2014. http://www.health.gov.au/internet/main/publishing.nsf/Content/mbsprimarycare_mbsitem_75andolder. 2015.
34. Bradford A, Kunik ME SP. Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis Assoc Disord. 2009;23(4):306–14.
35. Borson S, Frank L BP. Improving dementia care: the role of screening and detection of cognitive impairment. Alzheimer’s Dement. 2013;9(2):151–9.
36. Boustani M, Peterson B HL. Screening for dementia in primary care: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2003;138(11):927–37.
37. Lin J, O’Connor E RR. Screening for cognitive impairment in older adults: An evidence update for the US Preventive Services Task Force. Agency Healthc Res Qual. 2013;107.
38. LoGiudice D, Waltrowicz W BK. Do memory clinics improve the quality of life of carers? A randomized pilot trial. nternational J Geriatr Psychiatry. 1999;14(8):626–32.
39. Meeuwsen EJ, Melis RJ VDAG. Effectiveness of dementia follow-up care by memory clinics or general practitioners: randomised controlled trial. BMJ. 2012;344:e3086.
40. Mitchell AJ S-FM. Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. J Neurol Neurosurg Psychiatry. 2008;79(12):1386–91.
41. Mitchell A S-FM. Rate of progression of mild cognitive impairment to dementia-Metaanalysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119(4):252–65.
42. Ward A, Tardiff S DC. Rate of conversion from prodromal Alzheimer’s disease to Alzheimer’s dementia: a systematic review of the literature. Dement Geriatr Cogn Dis Extra. 2013;3(1):320–32.
43. Burns A, Iliffe S. Dementia. BMJ. 2009;338(75).
44. Brodaty H, Connors M PD. Dementia: 14 essentials of assessment and care planning. Med Today. 2013;14(8):18–27.
45. Noel-Storr AH, Flicker L RC. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. Alzheimer’s Dement. 2013;9(3):e96–105.
46. Jack CR, Jr., Albert MS KD. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7(3):257–62.
47. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement [Internet]. 2011;7(3):263–9.
48. Albert MS, DeKosky ST DD. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7(3):270–9.
49. Zhang S, Smailagic N HC. 11C-PIB-PET for the early diagnosis of Alzheimer?s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 20114;7.
50. AM. C. The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch Intern Med. 2003;163(18):2219–29.
51. Bloudek LM, Spackman DE BM. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J Alzheimer’s Dis. 2011;26(4):267–45.
52. Ontario HQ. The appropriate use of neuroimaging in the diagnostic work-up of dementia: an evidence-based analysis. Ont Heal Technol Assess Ser Ontario. 2014;1–64.
53. Beynon R, Sterne JA WG. Is MRI better than CT for detecting a vascular component to dementia? A systematic review and meta-analysis. BMC Neurol. 2012;12(33).
54. Medical Services Advisory Committee. Application No. 1195 – F-18 fluorodeoxyglucose positron emission tomography (FDG PET) for the diagnosis of Alzheimer’s disease. Public Summary Document. Canberra: Australian Government Departmen, 2015
55. Smailagic N, Vacante M, Hyde C, et al. 18F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015;1.
56. Dougall NJ, Bruggink S EK. Systematic review of the diagnostic accuracy of 99mTc-HMPAOSPECT in dementia. Am J Geriatr Psychiatry. 2004;12(6):554–70.
57. American Journal of Geriatric Psychiatry. A Syst Rev (Vol 2) Stock Swedish Counc Technol Assess Heal. 2008; 14 (10):118-26
58. Dobert N, Pantel J FL. Diagnostic value of FDG-PET and HMPAO-SPECT in patients with mild dementia and mild cognitive impairment: metabolic index and perfusion index. Dement Geriatr Cogn Disord. 2005;20(2):63–70.
59. Doran M, Vinjamuri S CJ. Single-photon emission computed tomography perfusion imaging in the differential diagnosis of dementia: a retrospective regional audit. Int J Clin Pr. 2005;59(4):496–500.
60. Logan-Sinclair PA DA. Diagnosing dementia in rural New South Wales. Aust J Rural Health. 2007;15(3):A83-8.
61. Frisoni GB, Bocchetta M CG. Imaging markers for Alzheimer disease: which vs how. Neurology. 2013;81(5):487–500.
62. Arkles RSJP, L.R.; Robertson, H.; Draper, B.; Chalkley, S.; Broe GA. Ageing, cognition and dementia in Australian Aboriginal and Torres Strait Islander peoples: a life cycle approach. REPORT. 2010.
63. Smith K, Flicker L DA. Assessing cognitive impairment in indigenous Australians: Reevaluation of the Kimberley Indigenous Cognitive Assessment in Western Australia and the Northern Territory. Aust Psychol. 2009;44(1):54–61.
64. Taylor KL, M.; Kuipers, P.; Stothers, K.; Piper K. Intercultural communications in remote Aboriginal Australian communities: what works in dementia education and management? Heal Sociol Rev. 2012;21(2):208–19.
65. Byszewski A, Molnar F A. Dementia diagnosis disclosure: A study of patient and caregiver perspectives. Alzheimer Dis Assoc Disord. 2007;21(2):107–14.
66. Prorok JC, Horgan S SD. Health care experiences of people with dementia and their caregivers: a meta-ethnographic analysis of qualitative studies. C Can Med Assoc J. 2013;185(14):E669-80.
67. Abley C, Manthorpe J BJ. Patients’ and carers’ views on communication and information provision when undergoing assessments in memory services. J Heal Serv Res Policy. 2013;18(3):167–73.
68. Leung P, Orrell M O V. Social support group interventions in people with dementia and mild cognitive impairment: a systematic review of the literature. Int J Geriatr Psychiatry. 2015;301(1):1–9.
69. National Institute for Health and Clinical Excellence SCIfE. A NICE–SCIE Guideline on supporting people with dementia and their carers in health and social care. Natl Clin Pract Guidel London. 2007;
70. Australian Health Ministers Advisory Council. National Framework for Action on Dementia 2014-2018. 2014
71. Parliament of Australia. Care and management of younger and older Australians living with dementia and behavioural and psychiatric symptoms of dementia: The Senate Community Affairs References Committee. 2014.
72. Beer C, Horner B, Flicker L, Scherer S, Lautenschlager NT, Bretland N, et al. A cluster-randomised trial of staff education to improve the quality of life of people with dementia living in residential care: The direct study. PLoS One. 2011;6(11):1–11.
73. Beer C, Horner B, Almeida OP, Scherer S, Lautenschlager NT, Bretland N, et al. Current experiences and educational preferences of general practitioners and staff caring for people with dementia living in residential facilities. BMC Geriatr. 2009;9:36.
74. Chenoweth L, King MT, Jeon YH, Brodaty H, Stein-Parbury J, Norman R, et al. Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial. Lancet Neurol. 2009;8(4):317–25.
75. Clare L, Whitaker R, Woods RT, Quinn C, Jelley H, Hoare Z, et al. AwareCare: a pilot randomized controlled trial of an awareness-based staff training intervention to improve quality of life for residents with severe dementia in long-term care settings. Int Psychogeriatr. 2013;25(1):128–39.
76. Deudon A, Maubourguet N, Gervais X, et al. Non-pharmacological management of behavioural symptoms in nursing homes. International Journal of Geriatric Psychiatry 2009;24(12):1386-95
77. Donath C, Grassel E, Grossfeld-Schmitz M, et al. Effects of general practitioner training and family support services on the care of home-dwelling dementia patients–results of a controlled cluster-randomized study. BMC Health Services Research 2010;10:314
78. Jeon YH, Luscombe G, Chenoweth L, et al. Staff outcomes from the caring for aged dementia care resident study (CADRES): a cluster randomised trial. International Journal of Nursing Studies 2012;49(5):508-18
79. Kuske B, Luck T, Hanns S, et al. Training in dementia care: A cluster-randomized controlled trial of a training program for nursing home staff in Germany. International Psychogeriatrics 2009;21(2):295-308
80. Leone E, Deudon A, Bauchet M, et al. Management of apathy in nursing homes using a teaching program for care staff: the STIM-EHPAD study. International Journal of Geriatric Psychiatry 2013;28(4):383-92
81. Leone E, Deudon A, Maubourguet N, et al. Methodological issues in the non pharmacological treatment of BPSD in nursing home–the TNM study. Journal of Nutrition, Health & Aging 2009;13(3):260-3
82. McCurry SM, LaFazia DM, Pike KC, et al. Development and evaluation of a sleep education program for older adults with dementia living in adult family homes. American Journal of Geriatric Psychiatry 2012;20(6):494-504
83. Pellfolk TJ, Gustafson Y, Bucht G, et al. Effects of a restraint minimization program on staff knowledge, attitudes, and practice: a cluster randomized trial. Journal of the American Geriatrics Society 2010;58(1):62-9
84. Resnick B, Cayo J, Galik E, et al. Implementation of the 6-week educational component in the Res-Care intervention: process and outcomes. Journal of Continuing Education in Nursing 2009;40(8):353-60
85. Resnick B, Gruber-Baldini AL, Zimmerman S, et al. Nursing home resident outcomes from the Res-Care intervention. Journal of the American Geriatrics Society 2009;57(7):1156-65
86. Spijker A, Wollersheim H, Teerenstra S, et al. Systematic care for caregivers of patients with dementia: a multicenter, cluster-randomized, controlled trial. American Journal of Geriatric Psychiatry 2011;19(6):521-31
87. Testad I, Ballard C, Bronnick K, et al. The effect of staff training on agitation and use of restraint in nursing home residents with dementia: a single-blind, randomized controlled trial. Journal of Clinical Psychiatry 2010;71(1):80-6
88. van der Kooij C, Droes R, de Lange J, et al. The implementation of integrated emotion-oriented care: Did it actually change the attitude, skills and time spent of trained caregivers? Dementia: The International Journal of Social Research and Practice 2013;12(5):536-50
89 Verkaik R, Francke AL, van Meijel B, et al. The effects of a nursing guideline on depression in psychogeriatric nursing home residents with dementia. International Journal of Geriatric Psychiatry 2011;26(7):723-32
90. Visser S, McCabe M, Hudgson C, et al. Managing behavioural symptoms of dementia: Effectiveness of staff education and peer support. Aging & Mental Health 2008;12(1):47-55
91. Waldorff FB, Siersma V, Nielsen B, et al. The effect of reminder letters on the uptake of an e-learning programme on dementia: a randomized trial in general practice. Family Practice 2009;26(6):466-71
92. Olazaran J, Muniz R, Reisberg B, et al. Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease. Neurology 2004;63(12):2348-53
93 Finnema E, Droes R, Ettema T, et al. The effect of integrated emotion-oriented care versus usual care on elderly persons with dementia in the nursing home and on nursing assistants: a randomized clinical trial. International Journal of Geriatric Psychiatry 2005;20:330-43
94. Hoeffer B, Talerico K, Rasin J, et al. Assisting cognitively impaired nursing home residents with bathing: effects of two bathing interventions on caregiving. Gerontologist 2006;46:524-32
95. Huizing A, Hamers JP, Gulpers M, et al. Short-term effects of an educational intervention on physical restraint use: a cluster randomized trial. BMC Geriatrics 2006;6:17
96. Kovach CR, Taneli Y, Dohearty P, et al. Effect of the BACE intervention on agitation of people with dementia. Gerontologist 2004;44:797-806
97. McCallion P, Toseland RW, Lacey D, et al. Educating nursing assistants to communicate more effectively with nursing home residents of dementia. Gerontologist 1999;39:546-58
98. Schrijnemaekers V, van Rossum E, Candel M, et al. Effects of emotion-oriented care on elderly people with cognitive impairment and behavioral problems. International Journal of Geriatric Psychiatry 2002;17:926-37
99. Teri L, Huda P, Gibbons L, et al. STAR: a dementia-specific training program for staff in assisted living residences. Gerontologist 2005;45:686-93
100. Testad I, Aasland A, Aarsland D. The effect of staff training on the use of restraint in dementia: a single-blind randomised controlled trial. International Journal of Geriatric Psychiatry 2005;20:587-90.
101. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999;99(6):779-85
102. Koloverou E, Esposito K, Giugliano D, et al. The effect of Mediterranean diet on the development of type 2 diabetes mellitus: a meta-analysis of 10 prospective studies and 136,846 participants. Metabolism: clinical and experimental 2014;63(7):903-11
103. Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA 2004; 292(12):1433-9.
104. Gillette Guyonnet S, Abellan Van Kan G, Alix E, et al. IANA (International Academy on Nutrition and Aging) Expert Group: weight loss and Alzheimer’s disease. The journal of nutrition, health & aging 2007; 11(1):38-48
105. Prince MA, E.; Guerchet, M.;Prina,M. Nutrition and dementia. A review of available research. London: Alzheimer’s Disease International (ADI), 2014.
106. Ettinger RL. Treatment planning concepts for the aging patient. Australian Dental Journal 2015;60(1 Suppl 1):71-85
107. Foltyn P. Ageing, dementia and oral health. Australian Dental Journal 2015; 60(1):86-94. 108. Chen X, Kistler C. Oral health care for older adults with serious illness: When and how? JAGS 2015;63(2):375-78.
109. AIHW 2012. Dementia in Australia. Cat. no. AGE 70. Canberra: AIHW
110. Department of Social Services. Commonwealth Home Support Programme: Good Practice Guide for Restorative Care Approaches (incorporating Wellness, and Reablement). Canberra: Australian Government, 2015.
112. McLaren AN, Lamantia MA, Callahan CM. Systematic review of non-pharmacologic interventions to delay functional decline in community-dwelling patients with dementia. Aging & Mental Health 2013;17(6):655-66
113. Kumar P, Tiwari SC, Goel A, et al. Novel occupational therapy interventions may improve quality of life in older adults with dementia. International Archives of Medicine 2014; 7 (1).
114. Wenborn J, Challis D, Head J, et al. Providing activity for people with dementia in care homes: a cluster randomised controlled trial. International Journal of Geriatric Psychiatry 2013;28(12):1296-304.
115. Forbes D, Thiessen EJ, Blake CM, et al. Exercise programs for people with dementia. Cochrane Database of Systematic Reviews 2013;12:CD006489
116. Hauer K, Schwenk M, Zieschang T, et al. Physical training improves motor performance in people with dementia: A randomized controlled trial. Journal of the American Geriatrics Society 2012;60(1):8-15
117. Suttanon P, Hill KD, Said CM, et al. Feasibility, safety and preliminary evidence of the effectiveness of a home-based exercise programme for older people with Alzheimer’s disease: A pilot randomized controlled trial. Clinical Rehabilitation 2013;27(5):427-38.
118. Tchalla AE, Lachal F, Cardinaud N, et al. Preventing and managing indoor falls with home-based technologies in mild and moderate Alzheimer’s disease patients: pilot study in a community dwelling. Dementia & Geriatric Cognitive Disorders 2013;36(3-4):251-61
119. Torkamani M, McDonald L, Aguayo IS, et al. A randomized controlled pilot study to evaluate a technology platform for the assisted living of people with dementia and their carers. Journal of Alzheimer’s Disease 2014;41(2):515-23.
120. Wesson J, Clemson L, Brodaty H, et al. A feasibility study and pilot randomised trial of a tailored prevention program to reduce falls in older people with mild dementia. BMC Geriatrics 2013;13:89
121. Gitlin LN, Corcoran M, Winter L, et al. A randomized, controlled trial of a home environmental intervention: Effect on efficacy and upset in caregivers and on daily function of persons with dementia. Gerontologist 2001;41(1):4-14
122. Gitlin LN, Winter L, Corcoran M, et al. Effects of the home Environmental Skill-Building Program on the caregiver-care recipient dyad: 6-month outcomes from the Philadelphia REACH initiative. Gerontologist 2003;43(4):532-46
123. Gitlin LN, Winter L, Dennis MP, et al. A biobehavioral home-based intervention and the well-being of patients with dementia and their caregivers: The COPE Randomized Trial. Jama-Journal of the American Medical Association 2010;304(9):983-91
124. Graff MJL, Vernooij-Dassen MJM, Thijssen M, et al. Community based occupational therapy for patients with dementia and their care givers: randomised controlled trial. British Medical Journal 2006;333(7580):1196-99
125. Gitlin LN, Winter L, Burke J, et al. Tailored activities to manage neuropsychiatric behaviors in persons with dementia and reduce caregiver burden: A randomized pilot study. American Journal of Geriatric Psychiatry 2008;16(3):229-39.
126. Gitlin LN, Hauck WW, Dennis MP, et al. Maintenance of effects of the home environmental skill-building program for family caregivers and individuals with Alzheimer’s disease and related disorders. Journals of Gerontology Series a-Biological Sciences and Medical Sciences 2005;60(3):368-74
127. Clare L. Assessment and intervention in dementia of Alzheimer type. In: Baddeley A, Wilson B, Kopelman M, eds. The Essential Handbook of Memory Disorders for Clinicians London: Wiley, 2004:255-83.
128. Little A, Volans P, Hemsley D, et al. The retention of new information in senile dementia. British Journal of Clinical Psychology 1986;25:71-72.
129. Woods B, Aguirre E, Spector AE, et al. Cognitive stimulation to improve cognitive functioning in people with dementia. The Cochrane database of systematic reviews 2012;2:CD005562.
130. Bahar-Fuchs A, Clare L, Woods B. Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer’s disease and vascular dementia. The Cochrane database of systematic reviews 2013;6:CD003260.
131. Lee GY, Yip CC, Yu EC, et al. Evaluation of a computer-assisted errorless learning-based memory training program for patients with early Alzheimer’s disease in Hong Kong: a pilot study. Clinical Interventions In Aging 2013;8:623-33.
132. Thom J, Clare L. Rationale for combined exercise and cognition-focused interventions to improve functional independence in people with dementia. Gerontology 2011;57:265-75.
133. Clare L, Evans SJ, Parkinson CH, et al. Goal setting in cognitive rehabilitation for people with early stage Alzheimer’s disease. Clinical Gerontologist 2011;34(3):220-36.
134. Bond M, Rogers G, Peters J, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No 111): a systematic review and economic model. Health Technology Assess 2012;16(21).
135. Maher-Edwards G, Dixon R, Hunter J, et al. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. International Journal of Geriatric Psychiatry 2011;26(5):536-44.
136. Hager K, Baseman AS, Nye JS, et al. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease. Neuropsychiatric Disease and Treatment 2014;10:391-401
137. Cummings JL, Farlow MR, Meng X, et al. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer’s disease. Clinical Drug Investigation 2010;30(1):41-9
138. Ashford JW, Adamson M, Beale T, et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia. Journal of Alzheimer’s Disease 2011;26 Suppl 3:331-6 226. Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA 2014;311(1):33-44
139. Fox C, Crugel M, Maidment I, et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double-blind placebo controlled trial. PLoS ONE 2012;7(5):e35185
. Herrmann N, Gauthier S, Boneva N, et al. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer’s disease. International Psychogeriatrics 2013;25(6):919-27
141. Saxton J, Hofbauer RK, Woodward M, et al. Memantine and functional communication in Alzheimer’s disease: results of a 12-week, international, randomized clinical trial. Journal of Alzheimer’s Disease 2012;28(1):109-18.
142. Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 2015;86(2):135-43.
143. Birks J, Craig D. Galantamine for vascular cognitive impairment. Cochrane Database of Systematic Reviews 2013;4:CD004746
144. Birks J, McGuinness B, Craig D. Rivastigmine for vascular cognitive impairment. Cochrane Database of Systematic Reviews: Reviews 2013; Issue 5
145. Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database of Systematic Reviews: Reviews 2004; Issue 1.
146. Tricco AC, Soobiah C, Berliner S, et al. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. CMAJ: Canadian Medical Association journal 2013;185(16):1393-401.
147. Schmidt R, Hofer E, Bouwman FH, et al. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. European journal of neurology: the official journal of the European Federation of Neurological Societies 2015;22(6):889-98.
148. Centre for Health Economics Monash University, University of South Australia Veterans’ Medicines Advice and Therapeutics Education Services, Department of Health and Ageing Pharmaceutical Policy Branch, et al. Post Market Review Pharmaceutical Benefits Scheme anti-dementia medicines to treat Alzheimer Disease.
149. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001;57(4):613-20.
150. Di Santo SG, Prinelli F, Adorni F, et al. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer’s disease. Journal of Alzheimer’s Disease 2013;35(2):349-61.
151. Birks J, McGuinness B, Craig D. Rivastigmine for vascular cognitive impairment. Cochrane Database of Systematic Reviews 2013;5:CD004744
152. Malouf R, Birks J. Donepezil for vascular cognitive impairment. The Cochrane database of systematic reviews 2004(1):Cd004395 doi: 10.1002/14651858.CD004395.pub2.
153. Roman GC, Salloway S, Black SE, et al. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke 2010;41(6):1213-21.
154. Lyketsos C, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002;288(12):1475-8.
155. Moore M, Zhu C, Clipp E. Informal costs of dementia care: estimates from the National Longitudinal Caregiver Study. J Gerontol B Psychol Sci Soc Sci 2001;56(4):S219-S28.
156. van der Linde RM, Stephan BC, Savva GM, et al. Systematic reviews on behavioural and psychological symptoms in the older or demented population. Alzheimer’s research & therapy 2012;4(4):28.
157. Brodaty H, Draper BL, LF. Behavioural and psychological symptoms of dementia: a seven-tiered model of service delivery. MJA 2003;178(5):231-34.
158. Cohen-Mansfield J, Thein K, Marx MS, et al. Efficacy of nonpharmacologic interventions for agitation in advanced dementia: A randomized, placebo-controlled trial. Journal of Clinical Psychiatry 2012;73(9):1255-61
159. Burns A, Byrne J, Ballard C, Holmes C. Sensory stimulation in dementia: An effective option for managing behavioural problems. BMJ: British Medical Journal. 2002;325:1312. 160. Bakker TJ, Duivenvoorden HJ, van der Lee J, et al. Integrative psychotherapeutic nursing home program to reduce multiple psychiatric symptoms of cognitively impaired symptoms of cognitively impaired patients and caregiver burden: Randomized controlled trial. The American Journal of Geriatric Psychiatry 2011;19(6):507-20
161. Burgener SC, Yang Y, Gilbert R, et al. The effects of a multimodal intervention on outcomes of persons with early-stage dementia. American Journal of Alzheimers Disease and Other Dementias 2008;23(4):382-94
162. McCurry SM, Gibbons LE, Logsdon RG, et al. Nighttime insomnia treatment and education for Alzheimer’s disease: A randomized, controlled trial. Journal of the American Geriatrics Society 2005;53(5):793-802
163. Sung HC, Chang SM, Lee WL, et al. The effects of group music with movement intervention on agitated behaviours of institutionalized elders with dementia in Taiwan. Complementary Therapies in Medicine 2006;14(2):113-19
164. Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behavioral management in patients with Alzheimer disease – A randomized controlled trial. Jama-Journal of the American Medical Association 2003;290(15):2015-22
165. Brooker DJ, Argyle E, Scally AJ, et al. The enriched opportunities programme for people with dementia: A cluster-randomised controlled trial in 10 extra care housing schemes. Aging & Mental Health 2011;15(8):1008-17
166. Van de Winckel A, Feys H, De Weerdt W, et al. Cognitive and behavioural effects of music-based exercises in patients with dementia. Clinical Rehabilitation 2004;18(3):253-60.
167. Hilgeman MM, Allen RS, Snow A, et al. Preserving Identity and Planning for Advance Care (PIPAC): Preliminary outcomes from a patient-centered intervention for individuals with mild dementia. Aging & Mental Health 2014;18(4):411-24
168. Lin LC, Yang MH, Kao CC, et al. Using acupressure and Montessori-based activities to decrease agitation for residents with dementia: a cross-over trial. Journal of the American Geriatrics Society 2009;57(6):1022-9
169. Maci T, Pira FL, Quattrocchi G, et al. Physical and cognitive stimulation in Alzheimer Disease. the GAIA Project: a pilot study. American Journal of Alzheimer’s Disease & Other Dementias 2012;27(2):107-13.
170. Stanley MA, Calleo J, Bush AL, et al. The Peaceful Mind program: A pilot test of a cognitive-behavioral therapy-based intervention for anxious patients with Dementia. The American Journal of Geriatric Psychiatry 2013;21(7):696-708
171. Achterberg WP, Gambassi G, Finne-Soveri H, et al. Pain in European long-term care facilities: a cross national study in Finland, Italy and The Netherlands. Pain 2010;148:70-74
172. Woods RT, Bruce E, Edwards RT, et al. REMCARE: reminiscence groups for people with dementia and their family caregivers – effectiveness and cost-effectiveness pragmatic multicentre randomised trial. Health Technology Assessment (Winchester, England) 2012;16(48), 1-116.
173. 295. Boerlage A, van Dijk M, Stronks D, et al. Pain prevalence and characteristics in three Dutch residential homes. European Journal of Pain 2008;12:910-16
174. Sawyer P, Lillis J, Bodner E, et al. Substantial daily pain among nursing home residents. Journal of the American Medical Directors Association 2007;8:158-65.
175. McMinn B, Draper B. Vocally disruptive behaviour in dementia: development of an evidence based practice guideline. Aging and Mental Health 2005;9:16-24
176. Persons AGSPoCPiO. The management of chronic pain in older persons. Geriatrics 1998;53(3):S8-S24.
177. Husebo B, Ballard C, Aarsland D. Pain treatment of agitation in patients with dementia: A systematic review. International Journal of Geriatric Psychiatry 2011;26(10):1012-18
178. Tosato M, Lukas A, van der Roest H, et al. Association of pain with behavioral and psychiatric symptoms among nursing home residents with cognitive impairment: results from the SHELTER study. Pain 2012;153:305-10.
179. De Deyn PP, Drenth AF, Kremer BP, et al. Aripiprazole in the treatment of Alzheimer’s disease. Expert Opin Pharmacother 2013;14(4):459-74.
180. Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. The American journal of psychiatry 2012;169(1):71-9
181. Peisah C, Chan DK, McKay R, et al. Practical guidelines for the acute emergency sedation of the severely agitated older patient. Intern Med J 2011;41(9):651-7.
182. Buffum M, Sands L, Miaskowski C, et al. A clinical trial of the effectiveness of regularly scheduled versus as-needed administration of acetaminophen in the management of discomfort in older adults with dementia. Journal of the American Geriatrics Society 2004;52:1093-97
183. Chibnall J, Tait R, Harman B, et al. Effect of acetaminophen on behavior, well-being and psychotropic medication use in nursing home residents with moderate-to-severe dementia. Journal of the American Geriatrics Society 2005;53:1921-29
184. Husebo B, Ballard C, Sandvik R, et al. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: a cluster randomised clinical trial. BMJ 2011;343:d4065.
185. Bains J, Birks J, Dening T. Antidepressants for treating depression in dementia. Cochrane Database of Systematic Reviews 2002; (4).
186. Sepehry AA, Lee PE, Hsiung GY, et al. Effect of selective serotonin reuptake inhibitors in Alzheimer’s disease with comorbid depression: a meta-analysis of depression and cognitive outcomes. Drugs ging 2012;29(10):793-806
187. Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 2011;378(9789):403-11
188. Banerjee S, Hellier J, Romeo R, et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial–a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technology. Assessment (Winchester, England) 2013;17(7):1-166
189. Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003;60(7):737-46.
190. Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database of Systematic Reviews 2011(2):CD008191.
191. Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 2014;311(7):682-91
192. Finkel SI, Mintzer JE, Dysken M, et al. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer’s disease in utpatients treated with donepezil. Int J Geriatr Psychiatry 2004;19(1):9-18.
193. Maglione M, Ruelaz Maher A, Hu J, et al. Off-label use of atypical antipsychotics: an update. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011.
194. Cooper C, Mukadam N, Katona C, et al. Systematic review of the effectiveness of pharmacologic interventions to improve quality of life and well-being in people with dementia (Provisional abstract). American Journal of Geriatric Psychiatry 2013; 21(2).
195. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294(15):1934-43
196. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database of Systematic Reviews 2002(2):CD002852.
197. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. The American journal of psychiatry 2004;161(6):1113-5.
198. Seitz DP, Gill SS, Herrmann N, et al. Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review. International Psychogeriatrics 2013;25(2):185-203.
199. Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 2002;26(4):494-504.
200. McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in Alzheimer’s disease. Cochrane Database of Systematic Reviews 2014;3:CD009178
201. Jansen Sandra L, Forbes D, Duncan V, et al. Melatonin for the treatment of dementia. Cochrane Database of Systematic Reviews 2011; (1).
202. Asayama KY, H; Ito,T; Suzuki,H; Kudo,Y; Endo,S;. Double blind study of melatonin effects on the sleepwake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. Journal of Nippon Medical School 2003;70(4):334-41
203. Singer C, Tractenberg RE, Kaye J, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease. Sleep 2003;26(7):893-901
204. Riemersma-van der Lek RF, Swaab DF, Twisk J, et al. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA 2008;299(22):2642-55
205. Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer’s disease. International psychogeriatrics / IPA 2001;13(2):233-40
206. Magai C, Kennedy G, Cohen CI, et al. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer’s disease. The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry 2000;8(1):66-74
207. Rosenberg PB, Drye LT, Martin BK, et al. Sertraline for the treatment of depression in Alzheimer disease. The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry 2010;18(2):136-45
208. Weintraub D, Rosenberg PB, Drye LT, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry 2010;18(4):332-40.
209. Auchus AP, Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer’s disease. The Journal of neuropsychiatry and clinical neurosciences 1997;9(4):591-3.
210. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011;306(12):1359-69.
211. Porsteinsson AP, Tatiot PN, Erb, R; Cox, C; Smith, E; Jakimovich, L; Noviasky, J; Kowalski, N; Holt, C J; Irvine, C. Placebo-controlled study of divalproex sodium for agitation in dementia The American Journal of Geriatric Psychiatry 2001;9(1):58-66
212. Tariot PN, Raman R, Jakimovich L, Schneider L, Porsteinsson A, Thomas R, Mintzer J, Brenner, Ronald; Schafer, Kim; Thal, Leon. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial The American Journal of Geriatric Psychiatry 2005;13(11):942-49
213. Sommer OHA, Olav; Cvancarova, Milada; Olsen, Inge C.; Selbaek, Geir; Engedal, Knut. Effect of Oxcarbazepine in the Treatment of Agitation and Aggression in Severe Dementia Dementia and Geriatric Cognitive Disorders 2009;27(2):155-63.
214. Gitlin LN, Schulz R. Family caregiving of older adults. In: Prohaska TR, Anderson LA, Binstock RH, eds. Public Health for an Aging Society. Baltimore: John Hopkins University Press, 2012.
215. Adelman R, Tmanova L, Delgado D, et al. Caregiver burden: A clinical review. JAMA 2014;311(10):1052-59.
216. ABS. Household and family projections. Australia: Australian Bureau of Statistics, 2004.
217. 341. Au A, Li S, Lee K, et al. The Coping with Caregiving Group Program for Chinese caregivers of patients with Alzheimer’s disease in Hong Kong. Patient Education & Counseling 2010;78(2):256-60
218 Carbonneau H, Caron CD, Desrosiers J. Effects of an adapted leisure education program as a means of support for caregivers of people with dementia. Archives of Gerontology & Geriatrics 2011;53(1):31-9
219. Charlesworth G, Shepstone L, Wilson E, et al. Befriending carers of people with dementia: randomised controlled trial. BMJ 2008;336(7656):1295-7
220. Charlesworth G, Shepstone L, Wilson E, et al. Does befriending by trained lay workers improve psychological well-being and quality of life for carers of people with dementia, and at what cost? A randomised controlled trial. Health Technology Assessment (Winchester, England) 2008;12(4):iii, v-ix, 1-78
221. Chien WT, Lee IY. Randomized controlled trial of a dementia care programme for families of home-resided older people with dementia. Journal of Advanced Nursing 2011;67(4):774-87
222. Davis JD, Tremont G, Bishop DS, et al. A telephone-delivered psychosocial intervention improves dementia caregiver adjustment following nursing home placement. International Journal of Geriatric Psychiatry 2011;26(4):380-7
223. Ducharme FC, Levesque LL, Lachance LM, et al. “Learning to become a family caregiver” efficacy of an intervention program for caregivers following diagnosis of dementia in a relative. Gerontologist 2011;51(4):484-94
224. Eloniemi-Sulkava U, Saarenheimo M, Laakkonen ML, et al. Family care as collaboration: effectiveness of a multicomponent support program for elderly couples with dementia. Randomized controlled intervention study. Journal of the American Geriatrics Society 2009;57(12):2200-8
225. Gaugler JE, Reese M, Mittelman MS. Effects of the NYU Caregiver Intervention-Adult Child on residential care placement. The Gerontologist 2013;53(6):985-97
226. Gavrilova SI, Ferri CP, Mikhaylova N, et al. Helping carers to care–the 10/66 dementia research group’s randomized control trial of a caregiver intervention in Russia. International Journal of Geriatric Psychiatry 2009;24(4):347-54
227. Guerra M, Ferri CP, Fonseca M, et al. Helping carers to care: the 10/66 dementia research group’s randomized control trial of a caregiver intervention in Peru. Revista Brasileira de Psiquiatria 2011;33(1):47-54
228. Joling KJ, van Marwijk HW, Smit F, et al. Does a family meetings intervention prevent depression and anxiety in family caregivers of dementia patients? A randomized trial. PLoS ONE 2012;7(1):e30936
229. Judge KS, Yarry SJ, Looman WJ, et al. Improved Strain and Psychosocial Outcomes for Caregivers of Individuals with Dementia: Findings from Project ANSWERS. Gerontologist 2013;53(2):280-92
230. Klodnicka Kouri K, Ducharme FC, Giroux F. A psycho-educational intervention focused on communication for caregivers of a family member in the early stage of Alzheimer’s disease: results of an experimental study. Dementia: The International Journal of Social Research and Practice 2011;10(3):435-53
231 Knapp M, King D, Romeo R, et al. Cost effectiveness of a manual based coping strategy programme in promoting the mental health of family carers of people with dementia (the START (STrAtegies for RelaTives) study): a pragmatic randomised controlled trial. BMJ 2013;347:f6342
232. Kuo LM, Huang HL, Huang HL, et al. A home-based training program improves Taiwanese family caregivers’ quality of life and decreases their risk for depression: a randomized controlled trial. International Journal of Geriatric Psychiatry 2013;28(5):504-13
233. Kurz A, Wagenpfeil S, Hallauer J, et al. Evaluation of a brief educational program for dementia carers: The AENEAS Study. International Journal of Geriatric Psychiatry 2010;25(8):861-69
234. Kwok T, Lam L, Chung J. Case management to improve quality of life of older people with early dementia and to reduce caregiver burden. Hong Kong Medical Journal 2012;18 Suppl 6:4-6
235. Kwok T, Wong B, Ip I, et al. Telephone-delivered psychoeducational intervention for Hong Kong Chinese dementia caregivers: a single-blinded randomized controlled trial. Clinical Interventions In Aging 2013;8:1191-7
236. Liddle J, Smith-Conway ER, Baker R, et al. Memory and communication support strategies in dementia: effect of a training program for informal caregivers. International Psychogeriatrics 2012;24(12):1927-42
237. Livingston G, Barber J, Rapaport P, et al. Clinical effectiveness of a manual based coping strategy programme (START, STrAtegies for RelaTives) in promoting the mental health of carers of family members with dementia: pragmatic randomised controlled trial. BMJ 2013;347:6276
238. Logsdon RG, Pike KC, McCurry SM, et al. Early-stage memory loss support groups: outcomes from a randomized controlled clinical trial. Journals of Gerontology Series B-Psychological Sciences & Social Sciences 2010;65(6):691-7
239. Losada A, Marquez-Gonzalez M, Romero-Moreno R. Mechanisms of action of a psychological intervention for dementia caregivers: effects of behavioral activation and modification of dysfunctional thoughts. International Journal of Geriatric Psychiatry 2011;26(11):1119-27
240. Martin-Carrasco M, Martin MF, Valero CP, et al. Effectiveness of a psychoeducational intervention program in the reduction of caregiver burden in Alzheimer’s disease patients’ caregivers. International Journal of Geriatric Psychiatry 2009;24(5):489-99
241. Martindale-Adams J, Nichols LO, Burns R, et al. A trial of dementia caregiver telephone support. Canadian Journal of Nursing Research 2013;45(4):30-48
242 Phung KTT, Waldorff FB, Buss DV, et al. A three-year follow-up on the efficacy of psychosocial interventions for patients with mild dementia and their caregivers: The multicentre, rater-blinded, randomised Danish Alzheimer Intervention Study (DAISY). BMJ Open 2013; 3 (11).
243. Sogaard R, Sorensen J, Waldorff FB, et al. Early psychosocial intervention in Alzheimer’s disease: Cost utility evaluation alongside the Danish Alzheimer’s Intervention Study (DAISY). BMJ Open 2014;4(1)
244. Stern RA, D’Ambrosio LA, Mohyde M, et al. At the crossroads: development and evaluation of a dementia caregiver group intervention to assist in driving cessation. Gerontology & Geriatrics Education 2008;29(4):363-82
245 Tremont G, Davis JD, Bishop DS, et al. Telephone-delivered psychosocial intervention reduces burden in dementia caregivers. Dementia: The International Journal of Social Research and Practice 2008;7(4):503-20
246. Waldorff F, Buss D, Eckermann A, et al. Efficacy of psychosocial intervention in patients with mild Alzheimer’s disease: The multicentre, rater blinded, randomised Danish Alzheimer Intervention Study (DAISY). BMJ: British Medical Journal 2012;345(7870):1-14
247. Wang LQ, Chien WT. Randomised controlled trial of a family-led mutual support programme for people with dementia. Journal of Clinical Nursing 2011;20(15-16):2362-6
248. Wang LQ, Chien WT, Lee IY. An experimental study on the effectiveness of a mutual support group for family caregivers of a relative with dementia in mainland China. Contemporary Nurse 2012;40(2):210-24
249. Gitlin LN, Winter L, Dennis MP, et al. Targeting and managing behavioral symptoms in individuals with dementia: a randomized trial of a nonpharmacological intervention. Journal of the American Geriatrics Society 2010;58(8):1465-74

Instituto de Evaluación Tecnológica en Salud

IETS Colombia - Instituto de Evaluación Tecnológica en Salud. Instituto de Evaluación Tecnológica en Salud. Fue creado en el 2011 según lo estipulado en la Ley 1438, como una corporación sin ánimo de lucro, con participación de entidades públicas y privadas. De acuerdo con el Departamento Administrativo de la Función Pública, nuestro Instituto es una entidad descentralizada del sector de la salud. Es la Agencia Nacional de Evaluación de Tecnología Sanitaria de Colombia, que genera evidencia con rigor científico para soportar la toma de decisiones, promueve el desarrollo de mejores políticas públicas y prácticas asistenciales en salud con el fin de contribuir al mejoramiento de la salud de los colombianos, y a la sostenibilidad del sistema con legitimidad, innovación, calidad, equidad y eficiencia.

Anterior Siguiente

6.11

6.12 Análisis del contexto (identificación y análisis de barreras)

Referencias

1. Arango C, Ayuso J, Vieta E, Bagney A, Baeza I, Bobes T, et al. Asociación Americana îe Psiquiatría, Manual diagnóstico y estadístico de los trastornos mentales (DSM-5®), 5a Eî. Arlington, VA, Asociación Americana îe Psiquiatría, 2014 ISB. 978-84-9835-810-0.

3. Julie MD and Ganguli MD. Dementia and Cognitive Impairment: Epidemiology, Diagnosis, and Treatment. Clin Geriatr Med 2014: 30 (3): 421–442

4. Gomez C, Hernandez G, Rojas A, Santacruz H, Uribe M. Psiquiatría clínica: diagnóstico y tratamiento en niños, adolescentes y adultos. Medica Panamericana. 2008 ISB: 9789588443010; Pag 410

5. Demencia: una prioridad de salud pública. Washington, DC: OPS, 2013 Disponible en: http://www.who.int/mental_health/publications/dementia_report_2012/es/

6. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001; 20 (357): 169–75

7. Consultado el 24 de febrero de 2017, Demencia Disponible: http://www.who.int/mediacentre/factsheets/fs362/es/

8. Fitzpatrick AL, Kuller LH, Lopez OL, Kawas CH, Jagust W. Survival following dementia onset: Alzheimer’s disease and vascular dementia. J Neurol Sci. 2005, 15;229-230.

11. Wimo A, Prince M. World Alzheimer Report 2010 – The Global Economic Impact of Dementia. Alzheimer’s Disease International London, 2010. 96

13. NHMRC. Clinical practice guidelines and principles of care for people with dementia. Australia; 2016. ISBN Online: 978-0-9945415-2-9.

14. Organización Mundial de la Salud (OMS). Guía De Intervención Mhgap [Internet]. Guía de Intervención mhGAP, 2011. 1-5

15. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: Advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol. 2010;63(12):1308–11.

16. Toolkit a R. Guideline Adaptation : Update. 2009.

17. Nice SCI for E. L -NICE-SCIE Guideline On Supporting People With Dementia and Their Carers In Health and Social Care. Practice. British; 2006. 66-68

18. NHMRC. Procedures and requirements for meeting the 2011 NHMRC standard for clinical practice guidelines: Version 1.1. Australia; 2011. 32

19. Grasel E, Wiltfang J, Kornhuber J. Non-drug therapies for dementia: an overview of the current situation with regard to proof of effectiveness. Dement Geriatr Cogn Disord. 2003;15:115–125.

21. Steinberg M, Corcoran C, Tschanz JT, et al. Risk factors for neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2006;21:824–83

22. Travers C, Gray L, Hubbard R. Evidence for the safety and quality issues associated with the care of patients with cognitive impairment in acute care settings: a rapid review October 2013; 140.

23. Sansoni JD, C.; Grootemaat, P.; Samsa, P.; Capell, J.; Westera A. Younger onset dementia: a literature review: Centre for Health Service Development. Univ Wollongong. 2014;

24. Duane F, Brasher K, Koch S. Living alone with dementia. Dementia. 2013;12(1):123–36.

25. Forbes DA, Morgan D, Janzen BL. Rural and Urban Canadians with Dementia: Use of Health Care Services. Can J Aging / La Rev Can du Vieil. 2010 Mar 31 [cited 2017 Jan 15];25(3):321.

26.

27. Koch T ISE-EP. Rapid appraisal of barriers to the diagnosis and management of patients with dementia in primary care: a systematic review. BMC Fam Pract. 2010;11(52).

28. Cattel C, Gambassi G SA. Correlates of delayed referral for the diagnosis of dementia in an outpatient population. journals Gerontol. 2000;55(2):98–102.

29. Bridges-Webb C, Giles B SC. Patients with dementia and their carers in general practice. Aust Fam Physician. 2006;35(11):923–4.

30. Radford K, Mack HA, Draper B, Chalkley S, Daylight G, Cumming R, et al. Prevalence of dementia in urban and regional Aboriginal Australians. Alzheimer’s Dement. 2015;11(3):271–9.

31. Smith K, Flicker L LN. High prevalence of dementia and cognitive impairment in Indigenous Australians. Neurology. 2008;71(19):1470–3.

32. Bunn F, Goodman C SK. Psychosocial Factors That Shape Patient and Carer Experiences of Dementia Diagnosis and Treatment: A Systematic Review of Qualitative Studies. PLoS One. 2012;9(10):1001331.

33. Health AGD of. Health assessment for people aged 75 years and older. 2014. http://www.health.gov.au/internet/main/publishing.nsf/Content/mbsprimarycare_mbsitem_75andolder. 2015.

34. Bradford A, Kunik ME SP. Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis Assoc Disord. 2009;23(4):306–14.

35. Borson S, Frank L BP. Improving dementia care: the role of screening and detection of cognitive impairment. Alzheimer’s Dement. 2013;9(2):151–9.

36. Boustani M, Peterson B HL. Screening for dementia in primary care: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2003;138(11):927–37.

37. Lin J, O’Connor E RR. Screening for cognitive impairment in older adults: An evidence update for the US Preventive Services Task Force. Agency Healthc Res Qual. 2013;107.

38. LoGiudice D, Waltrowicz W BK. Do memory clinics improve the quality of life of carers? A randomized pilot trial. nternational J Geriatr Psychiatry. 1999;14(8):626–32.

39. Meeuwsen EJ, Melis RJ VDAG. Effectiveness of dementia follow-up care by memory clinics or general practitioners: randomised controlled trial. BMJ. 2012;344:e3086.

40. Mitchell AJ S-FM. Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. J Neurol Neurosurg Psychiatry. 2008;79(12):1386–91.

41. Mitchell A S-FM. Rate of progression of mild cognitive impairment to dementia-Metaanalysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119(4):252–65.

42. Ward A, Tardiff S DC. Rate of conversion from prodromal Alzheimer’s disease to Alzheimer’s dementia: a systematic review of the literature. Dement Geriatr Cogn Dis Extra. 2013;3(1):320–32.

43. Burns A, Iliffe S. Dementia. BMJ. 2009;338(75).

44. Brodaty H, Connors M PD. Dementia: 14 essentials of assessment and care planning. Med Today. 2013;14(8):18–27.

45. Noel-Storr AH, Flicker L RC. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. Alzheimer’s Dement. 2013;9(3):e96–105.

46. Jack CR, Jr., Albert MS KD. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7(3):257–62.

48. Albert MS, DeKosky ST DD. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7(3):270–9.

49. Zhang S, Smailagic N HC. 11C-PIB-PET for the early diagnosis of Alzheimer?s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 20114;7.

50. AM. C. The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch Intern Med. 2003;163(18):2219–29.

51. Bloudek LM, Spackman DE BM. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J Alzheimer’s Dis. 2011;26(4):267–45.

52. Ontario HQ. The appropriate use of neuroimaging in the diagnostic work-up of dementia: an evidence-based analysis. Ont Heal Technol Assess Ser Ontario. 2014;1–64.

53. Beynon R, Sterne JA WG. Is MRI better than CT for detecting a vascular component to dementia? A systematic review and meta-analysis. BMC Neurol. 2012;12(33).

54. Medical Services Advisory Committee. Application No. 1195 – F-18 fluorodeoxyglucose positron emission tomography (FDG PET) for the diagnosis of Alzheimer’s disease. Public Summary Document. Canberra: Australian Government Departmen, 2015

55. Smailagic N, Vacante M, Hyde C, et al. 18F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015;1.

56. Dougall NJ, Bruggink S EK. Systematic review of the diagnostic accuracy of 99mTc-HMPAOSPECT in dementia. Am J Geriatr Psychiatry. 2004;12(6):554–70.

57. American Journal of Geriatric Psychiatry. A Syst Rev (Vol 2) Stock Swedish Counc Technol Assess Heal. 2008; 14 (10):118-26

58. Dobert N, Pantel J FL. Diagnostic value of FDG-PET and HMPAO-SPECT in patients with mild dementia and mild cognitive impairment: metabolic index and perfusion index. Dement Geriatr Cogn Disord. 2005;20(2):63–70.

59. Doran M, Vinjamuri S CJ. Single-photon emission computed tomography perfusion imaging in the differential diagnosis of dementia: a retrospective regional audit. Int J Clin Pr. 2005;59(4):496–500.

60. Logan-Sinclair PA DA. Diagnosing dementia in rural New South Wales. Aust J Rural Health. 2007;15(3):A83-8.

61. Frisoni GB, Bocchetta M CG. Imaging markers for Alzheimer disease: which vs how. Neurology. 2013;81(5):487–500.

62. Arkles RSJP, L.R.; Robertson, H.; Draper, B.; Chalkley, S.; Broe GA. Ageing, cognition and dementia in Australian Aboriginal and Torres Strait Islander peoples: a life cycle approach. REPORT. 2010.

63. Smith K, Flicker L DA. Assessing cognitive impairment in indigenous Australians: Reevaluation of the Kimberley Indigenous Cognitive Assessment in Western Australia and the Northern Territory. Aust Psychol. 2009;44(1):54–61.

64. Taylor KL, M.; Kuipers, P.; Stothers, K.; Piper K. Intercultural communications in remote Aboriginal Australian communities: what works in dementia education and management? Heal Sociol Rev. 2012;21(2):208–19.

65. Byszewski A, Molnar F A. Dementia diagnosis disclosure: A study of patient and caregiver perspectives. Alzheimer Dis Assoc Disord. 2007;21(2):107–14.

66. Prorok JC, Horgan S SD. Health care experiences of people with dementia and their caregivers: a meta-ethnographic analysis of qualitative studies. C Can Med Assoc J. 2013;185(14):E669-80.

67. Abley C, Manthorpe J BJ. Patients’ and carers’ views on communication and information provision when undergoing assessments in memory services. J Heal Serv Res Policy. 2013;18(3):167–73.

68. Leung P, Orrell M O V. Social support group interventions in people with dementia and mild cognitive impairment: a systematic review of the literature. Int J Geriatr Psychiatry. 2015;301(1):1–9.

69. National Institute for Health and Clinical Excellence SCIfE. A NICE–SCIE Guideline on supporting people with dementia and their carers in health and social care. Natl Clin Pract Guidel London. 2007;

70. Australian Health Ministers Advisory Council. National Framework for Action on Dementia 2014-2018. 2014

71. Parliament of Australia. Care and management of younger and older Australians living with dementia and behavioural and psychiatric symptoms of dementia: The Senate Community Affairs References Committee. 2014.

72. Beer C, Horner B, Flicker L, Scherer S, Lautenschlager NT, Bretland N, et al. A cluster-randomised trial of staff education to improve the quality of life of people with dementia living in residential care: The direct study. PLoS One. 2011;6(11):1–11.

73. Beer C, Horner B, Almeida OP, Scherer S, Lautenschlager NT, Bretland N, et al. Current experiences and educational preferences of general practitioners and staff caring for people with dementia living in residential facilities. BMC Geriatr. 2009;9:36.

74. Chenoweth L, King MT, Jeon YH, Brodaty H, Stein-Parbury J, Norman R, et al. Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial. Lancet Neurol. 2009;8(4):317–25.

75. Clare L, Whitaker R, Woods RT, Quinn C, Jelley H, Hoare Z, et al. AwareCare: a pilot randomized controlled trial of an awareness-based staff training intervention to improve quality of life for residents with severe dementia in long-term care settings. Int Psychogeriatr. 2013;25(1):128–39.

76. Deudon A, Maubourguet N, Gervais X, et al. Non-pharmacological management of behavioural symptoms in nursing homes. International Journal of Geriatric Psychiatry 2009;24(12):1386-95

77. Donath C, Grassel E, Grossfeld-Schmitz M, et al. Effects of general practitioner training and family support services on the care of home-dwelling dementia patients–results of a controlled cluster-randomized study. BMC Health Services Research 2010;10:314

78. Jeon YH, Luscombe G, Chenoweth L, et al. Staff outcomes from the caring for aged dementia care resident study (CADRES): a cluster randomised trial. International Journal of Nursing Studies 2012;49(5):508-18

79. Kuske B, Luck T, Hanns S, et al. Training in dementia care: A cluster-randomized controlled trial of a training program for nursing home staff in Germany. International Psychogeriatrics 2009;21(2):295-308

80. Leone E, Deudon A, Bauchet M, et al. Management of apathy in nursing homes using a teaching program for care staff: the STIM-EHPAD study. International Journal of Geriatric Psychiatry 2013;28(4):383-92

81. Leone E, Deudon A, Maubourguet N, et al. Methodological issues in the non pharmacological treatment of BPSD in nursing home–the TNM study. Journal of Nutrition, Health & Aging 2009;13(3):260-3

82. McCurry SM, LaFazia DM, Pike KC, et al. Development and evaluation of a sleep education program for older adults with dementia living in adult family homes. American Journal of Geriatric Psychiatry 2012;20(6):494-504

83. Pellfolk TJ, Gustafson Y, Bucht G, et al. Effects of a restraint minimization program on staff knowledge, attitudes, and practice: a cluster randomized trial. Journal of the American Geriatrics Society 2010;58(1):62-9